RT Journal Article
SR Electronic
T1 Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.28.21261159
DO 10.1101/2021.07.28.21261159
A1 Stephen J. Thomas
A1 Edson D. Moreira, Jr.
A1 Nicholas Kitchin
A1 Judith Absalon
A1 Alejandra Gurtman
A1 Stephen Lockhart
A1 John L. Perez
A1 Gonzalo Pérez Marc
A1 Fernando P. Polack
A1 Cristiano Zerbini
A1 Ruth Bailey
A1 Kena A. Swanson
A1 Xia Xu
A1 Satrajit Roychoudhury
A1 Kenneth Koury
A1 Salim Bouguermouh
A1 Warren V. Kalina
A1 David Cooper
A1 Robert W. Frenck, Jr.
A1 Laura L. Hammitt
A1 Özlem Türeci
A1 Haylene Nell
A1 Axel Schaefer
A1 Serhat Ünal
A1 Qi Yang
A1 Paul Liberator
A1 Dina B. Tresnan
A1 Susan Mather
A1 Philip R. Dormitzer
A1 Uğur Şahin
A1 William C. Gruber
A1 Kathrin U. Jansen
A1 C4591001 Clinical Trial Group
YR 2021
UL http://medrxiv.org/content/early/2021/07/28/2021.07.28.21261159.abstract
AB Background BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. BNT162b2 is highly efficacious against COVID-19 and is currently authorized for emergency use or conditional approval worldwide. At the time of authorization, data beyond 2 months post-vaccination were unavailable.Methods In an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy study, 44,165 ≥16-year-old participants and 2,264 12-15-year-old participants were randomized to receive 2 doses, 21 days apart, of 30 µg BNT162b2 or placebo. Study endpoints reported here are vaccine efficacy (VE) against laboratory-confirmed COVID-19 and safety data, both up to 6 months post-vaccination.Results BNT162b2 continued to be safe and well tolerated. Few participants had adverse events leading to study withdrawal. VE against COVID-19 was 91% (95% CI 89.0-93.2) through up to 6 months of follow-up, among evaluable participants and irrespective of previous SARS-CoV-2 infection. VE of 86%-100% was seen across countries and in populations with diverse characteristics of age, sex, race/ethnicity, and COVID-19 risk factors in participants without evidence of previous SARS-CoV-2 infection. VE against severe disease was 97% (95% CI 80.3−99.9). In South Africa, where the SARS-CoV-2 variant of concern, B.1.351 (beta), was predominant, 100% (95% CI 53.5, 100.0) VE was observed.Conclusion With up to 6 months of follow-up and despite a gradually declining trend in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing COVID-19. (ClinicalTrials.gov number, NCT04368728)Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdfClinical TrialNCT04368728Funding StatementSupported by BioNTech and Pfizer.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was conducted in accordance with the protocol, the ethical principles derived from international guidelines including the International Council for Harmonisation Good Clinical Practice Guidelines, the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, and applicable laws and regulations (including applicable privacy laws). An independent data monitoring committee reviewed efficacy and unblinded safety data. Institutional Review Board or Ethics Committee approval was obtained for each site prior to enrollment of any study participant. The list of Institutional Review Board Committees is summarized at the end of the Supplementary Appendix.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual anonymized participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information.Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual anonymized participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information.